Sec Form 3 Filing - Athyrium Opportunities IV Acquisition 2 LP @ RVL Pharmaceuticals plc - 2022-08-08

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Athyrium Opportunities IV Acquisition 2 LP 2. Issuer Name and Ticker or Trading Symbol RVL Pharmaceuticals plc [ RVLP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 505 FIFTH AVENUE, FLOOR 18 3. Date of Earliest Transaction (MM/DD/YY) 08/08/2022 (Street) NEW YORK, NY10017 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 8,148,832 I See footnotes( 1 )( 2 ) Ordinary Shares 6,451,612 I See footnotes( 2 )( 3 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants $ 3.1 10/12/2021 04/14/2025 Ordinary Shares 2,000,000 I See footnote( 1 )( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Athyrium Opportunities IV Acquisition 2 LP 505 FIFTH AVENUE, FLOOR 18 NEW YORK, NY10017 X Athyrium Opportunities IV Co-invest 2 LP 505 FIFTH AVENUE, FLOOR 18 NEW YORK, NY10017 X Athyrium Opportunities Associates IV LP 505 FIFTH AVENUE, FLOOR 18 NEW YORK, NY10017 X Athyrium Opportunities Associates IV GP LLC 505 FIFTH AVENUE, FLOOR 18 NEW YORK, NY10017 X Athyrium Funds GP Holdings LLC 505 FIFTH AVENUE, FLOOR 18 NEW YORK, NY10017 X Athyrium Opportunities Associates IV Co-Invest LLC 505 FIFTH AVENUE, FLOOR 18 NEW YORK, NY10017 X Ferrell Jeffrey 505 FIFTH AVENUE, FLOOR 18 NEW YORK, NY10017 X Signatures /s/ Athyrium Opportunities IV Acquisition 2 LP, by Athyrium Opportunities Associates IV LP, its General Partner, by Athyrium Opportunities Associates IV GP LLC, its General Partner, by Andrew Hyman, Senior Vice President, Secretary 08/12/2022 Signature of Reporting Person Date /s/ Athyrium Opportunities Associates IV LP, by Athyrium Opportunities Associates IV GP LLC, its General Partner, by Andrew Hyman, Senior Vice President, Secretary 08/12/2022 Signature of Reporting Person Date /s/ Athyrium Opportunities Associates IV GP LLC, by Andrew Hyman, Senior Vice President, Secretary 08/12/2022 Signature of Reporting Person Date /s/ Athyrium Opportunities IV Co-Invest 2 LP, by Athyrium Opportunities IV Co-Invest LLC, its General Partner, by Andrew Hyman, Senior Vice President, Secretary 08/12/2022 Signature of Reporting Person Date /s/ Athyrium Opportunities Associates IV Co-Invest LLC, by Andrew Hyman, Senior Vice President, Secretary 08/12/2022 Signature of Reporting Person Date /s/ Athyrium Funds GP Holdings LLC, by Jeffrey A. Ferrell, Managing Member 08/12/2022 Signature of Reporting Person Date /s/ Jeffrey A. Ferrell 08/12/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents securities held by Athyrium Opportunities IV Acquisition 2 LP ("Acquisition 2"). Athyrium Opportunities Associates IV GP LLC ("Associates IV GP") is the general partner of Athyrium Opportunities Associates IV LP, which is the general partner of Acquisition 2. Athyrium Funds GP Holdings LLC ("Holdings") is the managing member of Associates IV GP. Jeffery Ferrell is the managing member of Holdings. ( 2 )Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. ( 3 )Represents securities held by Athyrium Opportunities IV Co-Invest 2 LP ("Co-Invest"). Athyrium Opportunities Associates IV Co-Invest LLC ("Co-Invest GP") is the general partner of Co-Invest. Holdings is the managing member of Co-Invest GP. Jeffery Ferrell is the managing member of Holdings.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.